门脉高压药物治疗进展  

New progress on drug therapy of portal hypertension

作　　者：王建荣[1,2] 陆文霞[1,2] 夏玉敬[1] 卢洁[1] 周莹群[1] 郭传勇[1] 

机构地区：[1]同济大学附属第十人民医院消化科,上海200072 [2]南京医科大学第一临床医学院,南京210029

出　　处：《世界临床药物》2016年第1期61-66,共6页World Clinical Drug

基　　金：上海卫生系统第二批重要疾病联合攻关项目(编号:2014ZYJB0201)

摘　　要：门脉高压是肝硬化失代偿期患者典型的临床表现,可导致如食管胃底静脉曲张破裂出血、难治性腹水及肝性脑病等严重的并发症。有效降低门脉高压有助于降低并发症发生率,改善患者预后,降低患者死亡率。目前临床常用于降低门脉高压的药物包括血管加压素、生长抑素类及β受体阻断剂等,两外尚有多种降低门脉高压药物处于研究阶段。本文综述目前降低门脉高压的药物临床应用及新药开发进展。Portal hypertension is a typical clinical manifestations of cirrhosis patients in liver decompensation period. Portal hypertension can lead to serious complications, such as esophagogastric variceal hemorrhage, refractory ascites and hepatic encephalopathy. To decrease portal pressure can help to improve prognosis and reduce complication and mortality. Vasopressin, somatostatin analogues and β-blockers are widely used in clinical practice to decrease the portal hypertension currently. Now there are still many other drugs on development stage. This paper reviews the progress on the drug therapy of portal hypertension.

关 键 词：门脉高压 门静脉压力 药物治疗 肝硬化 

分 类 号：R972.4[医药卫生—药品] R575.2[医药卫生—药学]